In our latest AACR Preview series we now turn our attention to the evolving KRAS niche of inhibitors and degraders.

It’s not that long ago we only had G12C mutations to talk about in terms of what was considered ‘druggable’ and now we have another mutant (G12D) with at least two agents in the clinic already and more soon to come.

Of course, there are also the pan inhibitors in the mix and these will be covered separately.

For now though, it’s the turn of the selective agents with much more going on than many observers may realise, including some interesting novel developments coming through…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by